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Abstract
Controlled human infection (CHI) models are gaining recognition as an
approach to accelerating vaccine development, for use in both non-endemic
and endemic populations: they can facilitate identification of the most promising
candidate vaccines for further trials and advance understanding of protective
immunity. Helminths present a continuing health burden in sub-Saharan Africa.
Vaccine development for these complex organisms is particularly challenging,
partly because protective responses are akin to mechanisms of allergy. A CHI
model for  (CHI-S) has been developed at LeidenSchistosoma mansoni 
University Medical Centre, the Netherlands. However, responses to
schistosome infections, and candidate vaccines, are likely to be different
among people from endemic settings compared to schistosome-naïve Dutch
volunteers. Furthermore, among volunteers from endemic regions who have
acquired immune responses through prior exposure, schistosome challenge
can be used to define responses associated with clinical protection, and thus to
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can be used to define responses associated with clinical protection, and thus to
guide vaccine development.  To explore the possibility of establishing the
CHI-S in Uganda, a Stakeholders’ Meeting was held in Entebbe in 2017.
Regulators, community members, researchers and policy-makers discussed
implementation challenges and recommended preparatory steps: risk
assessment; development of infrastructure and technical capacity to produce
the infectious challenge material in Uganda; community engagement from
Parliamentary to grass-roots level; pilot studies to establish approaches to
assuring fully informed consent and true voluntariness, and strategies for
selection of volunteers who can avoid natural infection during the 12-week
CHI-S; the building of regulatory capacity; and the development of study
protocols and a product dossier in close consultation with ethical and regulatory
partners. It was recommended that, on completion, the protocol and product
dossier be reviewed for approval in a joint meeting combining ethical,
regulatory and environment management authorities. Most importantly,
representatives of schistosomiasis-affected communities emphasised the
urgent need for an effective vaccine and urged the research community not to
delay in the development process.
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Introduction
Effective vaccines have proven extremely useful in the pre-
vention of infectious diseases, but are still lacking for major 
poverty-related and neglected infections, including helminth 
infections. The conventional approach to vaccine development, 
testing efficacy in human subjects in large Phase III trials after 
safety and immunogenicity are confirmed through smaller Phase 
I and II trials, is lengthy and extremely costly. An alternative 
approach, to identify the most promising candidate vaccines 
through controlled human infection (CHI) models (typically 
referred to as Phase IIa), is gaining acceptance and applica-
tion for infections including malaria, typhoid and others: to date 
about 22,000 volunteers have been infected, safely, with 23 
different pathogens1–4.
Schistosomiasis is a major parasitic infectious disease, con-
sidered second only to malaria as a parasitic cause of morbidity 
and mortality5. The current approach to control schistosomiasis 
is through mass drug administration (MDA) with praziquantel, 
but this is limited by high rates of re-infection and there are 
concerns about the possible emergence of drug resistance6,7. An 
effective vaccine would be an extremely valuable control tool but 
vaccine development for this complex organism is challenging. 
In a bid to accelerate this, Meta Roestenberg and colleagues 
at the Leiden University Medical Centre have developed a 
controlled human infection model for Schistosoma mansoni 
(CHI-S) and tested it among Dutch volunteers. However, the 
response to Schistosoma infection, and to candidate vaccines, 
is likely to differ markedly among people from endemic African 
populations (where vaccines are most needed and where peo-
ple are exposed to an abundance of potentially immunomodulat-
ing infections) compared to European volunteers. Furthermore, 
individuals from endemic populations may display some resist-
ance to CHI-S due to prior schistosome exposure. Vaccine 
development against several pathogens has been informed 
by studies in which naturally acquired immune responses are 
correlated with clinical protection, in order to inform vaccine 
developers on ideal antigens, epitopes and protective thresh-
olds. Thus challenge studies among volunteers from endemic 
settings, who have naturally acquired immunity, have the poten-
tial also to accelerate the development of the next generation 
of vaccines by allowing desirable immune responses to be 
identified and prioritised. Implementation of the CHI-S model 
in an endemic setting would therefore provide critical additional 
information on markers of protective immunity and on 
immunogenicity, safety and efficacy of candidate vaccines. 
As a first step towards establishing the CHI-S in an endemic 
setting, we held a stakeholders meeting in Entebbe, Uganda, 
in November 2017, to identify key challenges and to develop 
strategies to address them. Meeting participants included rep-
resentatives of Uganda’s Ministry of Health (Vector Control 
Division), National Council for Science and Technology, National 
Drug Authority and National Environment Management Author-
ity; researchers and clinicians who manage schistosomiasis 
and its complications; chairpersons, committee members 
and community representatives from various Ugandan ethics 
fora across the country (the Uganda Virus Research Institute, 
Makerere University and Mbarara University); representa-
tives of potential volunteer communities (Makerere University 
students and community representatives from Koome Islands 
in Lake Victoria); colleagues with experience of implement-
ing controlled human malaria infections (CHMI) from Kenya 
and with ethics expertise from Kenya and Malawi; and the team 
who developed the CHI-S from Leiden. Deliberations were 
informed by the earlier work on CHMI in Kenya, and by the 
proceedings of the meeting on CHI models held in Malawi in 
June 20178. We here report proceedings of the Uganda meeting.
Schistosomiasis
Schistosomiasis is estimated to affect 230 million people world-
wide, the majority of them in sub-Saharan Africa9. In Uganda, 
schistosomiasis was first described in the 1900s and was 
recognised as a serious public health problem in the 1950s10. 
Mapping, and the development of a control plan in the 1990s, 
provided a strong basis for the work of the Schistosomiasis 
Control Initiative, which launched its programme of control 
by Mass Drug Administration using praziquantel in Uganda 
in 2003. Initial results from MDA were promising11 but recent 
data show that, despite enhanced coverage, both prevalence 
and intensity of infection remain high in “hot spot” lake-
shore communities. It is increasingly evident that MDA alone 
will not be adequate to achieve WHO’s target of elimination 
of schistosomiasis as a public health problem by 2030. Of 
Uganda’s population of 36 million, more than 4 million are 
estimated to be infected with schistosomiasis, and 55% of 
the present population is estimated to be at risk12. 
Adult Schistosoma worms reside in blood vessels around the 
gut (S. mansoni, S. intercalatum and S. japonicum) or urinary 
bladder (S. haematobium), where the female lays eggs which 
are excreted through the intestinal or bladder wall and voided 
in stool or urine. In water, each egg hatches producing a single 
miracidium. This enters the intermediate snail host where it 
multiplies asexually, producing identical cercariae. Cercariae are 
shed into the water where they again infect the human host by 
penetrating through the skin (Figure 1)9. 
Humans sometimes experience cercarial dermatitis in response 
to the penetrating parasites and a minority develop acute schis-
tosomiasis syndrome (“Katayama Fever”) in reaction to an 
initial infection. However, most serious disease caused by schis-
tosome infection is due to the eggs. Besides being excreted 
in stool or urine, many eggs also find their way into other 
tissues, notably the liver: progressive liver fibrosis results in 
portal hypertension, splenomegaly, and ascites; oesophageal 
varices develop which can lead to death through uncontrolled 
haemorrhage9. Effective management, for example by repeated, 
endoscopic band ligation of the varices13, is seldom available in 
the resource-limited settings where schistosomiasis is common: 
upper gastrointestinal bleeding, resulting from S. mansoni-
induced periportal fibrosis is a common complaint in primary 
health care in Northern Uganda, along the course of the Nile14,15. 
Hepatosplenic schistosomiasis is also associated with stunted 
growth and anaemia, leucopenia and thrombocytopenia. 
Occasionally eggs can be found in the spinal cord or brain, causing 
neuropathology9. 
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Vaccines for schistosomiasis
A vaccine for schistosomiasis has been ranked among the top 
10 vaccines that need to be developed urgently16. Schistosomes 
are large, multicellular animals that have evolved to co-exist 
with their human host. The immunoregulatory properties of 
schistosomes, which enable them to live in the portal vascula-
ture without immune clearance, are likely to impede vaccine 
development17. The complex interplay between T-helper (Th)1, 
Th2 and regulatory responses is still incompletely under-
stood. Schistosome killing is mediated by antibody responses, 
and particularly by Immunoglobulin (Ig)E18, presenting the 
risk that an effective IgE-inducing vaccine might induce 
allergic reactions, especially among previously-exposed indi-
viduals from endemic populations (as in the case of a candi-
date hookworm vaccine19). T-helper (Th)2 response profiles 
are therefore undesirable. Th1 responses must be targeted. In 
animal models a Th1 response has been shown to be able to 
participate in immunity against schistosomes20, but it is not yet 
certain which Th1 responses can induce protective immunity 
and correlates of protection have not been identified. An ideal 
anti-schistosome vaccine would be suitable for use among 
young children in endemic settings, as well as adults in high-
risk occupations; it would achieve 75% reduction in infection 
intensity (assessed by circulating antigen or egg production); it 
would require administration of, at most, two doses; it would 
induce protection lasting at least five to 10 years21; it would 
not induce IgE; and it would be suitable to co-administer with 
MDA.
Attenuated whole organisms from some helminth species, 
including schistosome cercariae, have been shown to induce 
protective immunity in animals22,23, but production of attenu-
ated cercariae for large-scale administration is not feasible, thus 
the current goal is to identify helminth antigens that induce pro-
tective responses, but not IgE. Approaches to this include the 
use of sera generated in animal studies using attenuated larvae, 
or from human population studies that determine resist-
ance to re-infection after MDA, together with recombinant 
antigens developed from the investigation of the parasite tran-
scriptome and proteome, to identify antigen- and stage-specific 
antibodies associated with protection24,25. To date, four antigens 
(SmTSP-2, Sm14, Smp80 and Sh28GST) have been identified 
and tested, and show promise of efficacy in animal models; three 
(SmTSP-2, Sm14, Smp80) are ready to enter Phase I trials 
and one (Sh28GST, Bilhvax) has undergone a Phase III trial 
(NCT00870649: this has been completed but no data have 
yet been released on the outcome of the trial). However, 
transcriptomic-proteomic approaches suggest many more can-
didates that could be evaluated as vaccine antigens, either sin-
gly or in combinations26–28. Unfortunately, the limited resources 
available for schistosome vaccine development restrict the 
number of candidates that can be taken forward. As yet, the 
value of animal models for predicting efficacy of, and responses 
to, schistosome vaccine candidates in humans is unknown. 
Murine models may not be the optimal platform; baboons are 
considered the most suitable, and have been used to further 
the SmTSP-2 vaccine candidate to phase I testing in humans, 
but they are expensive and reagents for immunological studies 
are limited. In general, animal models have been of great 
utility in asking fundamental questions regarding immunology 
and demonstrating proof-of-principle of particular vaccina-
tion strategies, but do not recapitulate precisely the physiology 
Figure 1. The life cycle of Schistosoma mansoni. During natural infection, individuals are usually infected with multiple cercariae, both male 
and female, which mature into adults, pair in the mesenteric blood vessels, and produce eggs, the main cause of pathology. In the controlled 
human infection model, single sex (male) cercariae are used to avoid the development of eggs and consequent pathology.
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of human infections, and therefore cannot be considered a sub-
stitute for human studies. Clinical testing of novel candidates in 
humans is needed to obtain true efficacy data.
The controlled human schistosome infection model
The CHI-S model addresses many of the roadblocks to devel-
opment of an effective vaccine for schistosomiasis (Table 1). 
The model alone will provide novel information on the evolu-
tion of immune responses following infection. Combined with 
a model “vaccine”, such as irradiated cercariae, it has the poten-
tial to identify correlates of protection, particularly protective 
Th1 responses that could be harnessed for vaccine develop-
ment. Then, used as a challenge in phase I vaccine trials, 
CHI-S will allow efficient and timely selection of potential vac-
cine candidates, and hence could improve and accelerate the 
vaccine development pipeline. Implemented in the endemic 
setting, CHI-S will take into account the impact of prior and 
current exposure to schistosome infection (including pre-natal 
exposure)29 and allow modelling of efficacy in target popula-
tions, and in association with praziquantel MDA. In addition, 
CHI-S offers potential for testing the efficacy of new 
drugs for treatment of schistosomiasis. 
The Leiden CHI-S has been developed with detailed attention 
to safety in both production and administration of the infectious 
challenge product. Because eggs are the main source of mor-
bidity and pathology, the CHI-S avoids permanent pathology 
by making use of single-sex infections. Using the labora-
tory lifecycle, individual snails are isolated and each snail is 
carefully infected with a single miracidium. This undergoes 
asexual reproduction in the snail and after five weeks 
produces thousands of cercariae of a single clone, and hence sin-
gle sex. Following several quality control steps and determina-
tion of male or female sex by PCR, male cercariae are used for 
the controlled infection of volunteers. This is done by taping 
a chamber of water containing a predetermined number of male 
cercariae onto the volunteer’s forearm for a 30-minute interval. 
Work towards an infection model using female cercariae is 
in progress, but male worms do better than females when not 
in pairs and the possibility of production of sterile eggs from 
females needs to be excluded. Successful infections can be 
detected (usually after six to 12 weeks) and quantified by meas-
uring circulating anodic antigen (CAA) levels in the blood: this 
is a protein which is secreted into the blood in large quantities 
by adult worms30. Volunteers are followed up for 12 weeks 
and then treated with praziquantel. The infected snails and 
preparation of cercariae are managed in customised, dedicated 
facilities following Good Manufacturing Practice guide-
lines. The volunteers are intentionally infected with the male 
cercariae, and followed up until after they are cured, under 
conditions analogous to a Phase I Clinical Trial.
Technical considerations for implementation of the CHI-S in 
Uganda principally comprise the preparation of cercariae for the 
inoculum. Because the shelf-life of cercariae is just two hours, 
cercarial production for human challenge must be done locally. 
In Leiden, the S. mansoni life cycle is maintained in ham-
sters using a laboratory strain of S. mansoni which originated 
in Puerto Rico and Biomphalaria glabrata snails; this snail spe-
cies is not endemic in Uganda. In Uganda, the laboratory life 
cycle has previously been maintained by the Vector Control 
Division of the Ministry of Health for another project, using 
mice and a range of endemic Biomphalaria species (including 
B. choanomphala, B. stanleyi, and B. sudanica)31, but it 
is not actively maintained at present. 
Options for preparing the inoculum in Uganda include 
(1) re-establishing the full S. mansoni laboratory life-cycle; 
(2) shipping cryopreserved miracidia or eggs from Leiden for 
snail infection and cercarial shedding in Entebbe (technologies for 
cryopreservation of miracidia or eggs still need to be developed); 
(3) shipping infected snails from Leiden for shedding in Entebbe.
The third option, of shipping infected snails, is currently the 
most feasible. Guidelines for shipping live snails (including 
infected snails), developed by the Danish Bilharzia Laboratory, 
Table 1. Road blocks to schistosome vaccine development and how controlled human infection models for 
schistosomiasis can help. (CHI-S) - Controlled human infection model for Schistosoma mansoni.
Road blocks How CHI-S can help
Vaccine candidates: 
Several vaccine candidates are available; but there 
are limited resources to take candidates forward
 ✓    CHI-S quickly identifies candidates most likely to induce 
protection
Animal models:  
Suitability of various animals for predicting responses 
to, and efficacy of, vaccine candidates in humans not 
known
 ✓   CHI-S provides direct evidence of responses in humans
Immunological road-blocks: 
•    Schistosomes induce regulatory responses which 
could impair vaccine immunogenicity
•    Schistosomes induce Th2 responses and IgE with 
accompanying risk of allergic phenomena
•    Th1 responses involved in protection not known in 
humans
•   Correlates of protection not known
 ✓    CHI-S describes evolution of immune responses 
following infection
 ✓    Combined with a model “vaccine” (such as irradiated 
cercariae, predicted to be effective) CHI-S identifies 
protective Th1 responses and correlates of protection
Page 5 of 17
AAS Open Research 2018, 1:2 Last updated: 06 AUG 2018
are available. These will need to be combined with Interna-
tional Air Transport Association (IATA) requirements for 
shipping of infectious material. It will be important to work 
with customs officials and handling agents to ensure efficient 
release on arrival in Uganda. This process will need to be 
piloted. A risk assessment will need to be undertaken, in 
collaboration with the Uganda National Environment Manage-
ment Authority (NEMA) regarding potential introduction of 
a new snail species and S. mansoni strain into Ugandan water 
bodies and risk management protocols will need to be imple-
mented to ensure that this does not occur. Facilities for housing 
and shedding the snails, and preparing the inoculum in 
accordance with GMP guidelines, will need to be established. 
Post-meeting, a fourth option for a truly-local Ugandan CHI-S 
was proposed. This would involve generating the inoculum 
by obtaining miracidia from stool samples of infected peo-
ple in Uganda, and using these to infect snails of a local spe-
cies in the laboratory. This would have advantages. The use of 
a non-endemic Schistosoma strain and of non-endemic snail 
species would be avoided. The model would be closer to real 
life in Uganda. Additional capacity would be built in-country. 
However, this approach would also bring additional challenges. 
The full life-cycle (option (1) above) would need to be estab-
lished in order to test the Ugandan schistosome strain obtained 
for praziquantel susceptibility before use in controlled human 
infections. And it would be more difficult to interpret any dif-
ferences in responses to vaccines or to infection between 
studies in Uganda and studies in Leiden (or elsewhere). 
Nevertheless, this remains an important option for further 
discussion.
Good clinical laboratory practice (GCLP) accredited facili-
ties and expertise for PCR (to confirm male sex of cercariae) are 
already available in Uganda, and plans are in place to provide 
equipment for high-sensitivity detection of infection by meas-
urement of serum CAA in 2018. Immunological expertise for 
the conduct of antibody ELISAs and cellular immune response 
assays is also available. However, training of the Ugandan team 
to undertake specific procedures, and to replicate quality control 
procedures that have been developed in Leiden, will be key. 
Protocol development and participant recruitment 
considerations for CHI-S in Uganda
Ugandan researchers have substantial experience of commu-
nity engagement and of conducting Phase I trials under Good 
Clinical Practice (GCP) conditions. However, the stakehold-
ers’ meeting recognised that enhanced attention to aspects of 
these activities would be required for the CHI-S. 
Full details of community engagement plans will be needed as 
part of the CHI-S protocol. There is need to involve opinion 
leaders, including members of Parliament such as the Parlia-
mentary Committee on Health, and Resident District Commis-
sioners and District Health Officers of the participating districts, 
as well as local council leaders, in order to prevent circulation 
of misinformation about the work. Populations of interest for 
CHI-S will include Ugandans not previously exposed to schis-
tosomiasis (perhaps from an urban setting) as well as those 
from schistosomiasis-endemic communities (prior exposure 
for inclusion or exclusion can be determined by measuring IgG 
antibody to schistosome egg antigen): experience in Kenya with 
the controlled human malaria infection (CHMI) model showed 
that participants coming from areas with no active transmis-
sion (Nairobi residents) had low baseline responses to malaria, 
and a challenge response similar to Europeans3, whereas 
those resident where active malaria transmission occurs had 
higher baseline responses - indicative of either recent or prior 
malaria exposure - and a distinct profile of response to challenge 
(Kapulu, Bejon personal communication).
Kenyan researchers involved university communities for their 
first CHMI studies32, but a few attendees of the Uganda meet-
ing expressed concern about specifically targeting students. 
Although adults, university students are often still depend-
ents and parents might have objections. It was agreed that vol-
unteers would be expected to inform their next of kin about 
their participation and that contact details for the next of 
kin must be provided in case of emergency. Critical to recruit-
ment, and to obtaining informed consent, would be the inclu-
sion of a test that clearly demonstrates a full understanding of 
the CHI-S model, and reassurance that participation is truly vol-
untary. Based on Leiden experience, the time taken by the team 
to know the potential volunteers, during the initial screening 
and recruitment procedures, is expected to be valuable in 
selecting those that will understand, and reliably comply 
with, the procedures.
Volunteers from endemic communities are likely to be actively 
infected with S. mansoni at the time of recruitment. Such infec-
tions will need to be treated with praziquantel before enrolment 
in the CHI-S. This may require more than one dose of treat-
ment; cure can be determined using the highly-sensitive CAA 
assay. For individuals from endemic communities, there is also 
a substantial risk of re-exposure during the 12-week follow-up 
period between the CHI-S infection and cure; natural infec-
tion may be added to the CHI-S infection. While the 
resulting risk to the volunteer would be comparable to their usual 
lifestyle, this would invalidate the results of the study. There-
fore, volunteers will need to be carefully selected to ensure that 
they are able and willing to avoid re-exposure. The 12-week 
duration of the CHI-S follow up means that admission to a 
facility (as practiced in some CHMI studies) would not be 
feasible. Follow up of a randomised, placebo group could be 
considered in order to assess whether there are substantial 
re-infection rates in a study group. 
The Uganda CHI-S protocol will be expected to meet all the 
requirements of a phase I trial. A data and safety monitoring 
board (DSMB) will be needed, as well as internal and exter-
nal monitoring. A realistic evaluation of risks to the volunteers 
must be included: the intensity of the risk is expected to be lower 
than for malaria (for example), such that hospital admission 
will not be necessary, but a 24-hour helpline will be needed. 
Treatability and methods of treatment of likely side effects and 
safety evaluations to be conducted must be mentioned. Insur-
ance provision will be necessary: post-meeting information 
indicated that this should be provided by a local company or 
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agent, but it was recognised that local insurance companies 
in Uganda are unfamiliar with clinical trials and education of 
these bodies is needed. Material transfer agreements will be 
required for protocols involving import of snails or miracidia, and 
for export of samples if assays are to be done outside Uganda; 
data sharing agreements, where necessary, would need to be 
developed and implemented.
Rates for compensation of lost time or income, and transport 
costs, to volunteers will need to be specified and it will be chal-
lenging to set amounts that recognise demands upon the volun-
teers but do not constitute an undue inducement, since almost 
any payment may be an inducement in Ugandan settings. 
Principles for setting the payments will include estimates of 
time and income loss from visits and reimbursement for trans-
port costs and other inconveniences. Time compensation should 
be adjusted to the average income or wages in a particular 
community (for example the Kenyan CHMI studies offered 
higher rates of compensation in Nairobi than in Kilifi, based 
on the premise that Nairobi was an urban setting with higher 
income than in the coastal town of Kilifi which is in a rural 
setting). It is generally considered that participants should not 
be compensated for risk, since this could be interpreted as an 
undue inducement to take risks.
Ethical and regulatory considerations for CHI-S in 
Uganda
The fundamental ethical issue of concern in relation to CHI 
models is the principle of non-maleficence, to do no harm: CHI 
models represent a new ethical challenge and dilemma – using 
harm with a view to achieving benefit. Historical atrocities 
involving deliberate infection of vulnerable populations have 
an important influence on thinking in this field. Guidelines 
governing the implementation of CHI models are not available in 
African countries. While guidelines would be desirable, these 
take a long time to be developed and approved. At the stake-
holders’ meeting, it was recommended that the principles 
articulated by the World Health Organisation (2016)33 and 
benchmarks developed at the Malawi meeting on Controlled 
Human Infection Models in Low Income Countries8 be employed 
to govern the ethical and regulatory approval process. These 
are set out in Table 2, which also identifies ways in which the 
Uganda CHI-S will address them. Among the benchmarks 
outlined, critical elements discussed included the following. 
First, ethical and regulatory standards governing CHI stud-
ies in Africa must be equivalent to, or above, the minimum 
human protection standards applied internationally, as well as 
locally. When necessary, the capacity of ethical and regula-
tory bodies must be built, as well as the capacity of researchers. 
Second, risks must be examined and evaluated before consider-
ing possible benefits; there must be a favourable benefit: risk 
ratio. Arguably the risk associated with a controlled human 
infection may be more justifiable in an endemic population 
than in an unaffected population. Third, all stakeholders must 
be fully informed; in particular, as discussed above, volun-
teers must fully understand the study, its risks, and benefits, 
and must be shown to do so. Contributions of social science 
research to identifying ways of achieving this were desirable. 
Table 2. Benchmarks identified in the Malawi framework, and approach to addressing them for the Uganda controlled 
human infection model for Schistosoma mansoni (CHI-S). DSMB - data and safety monitoring board.
Malawi framework benchmarks Uganda CHI-S
1 Issue of national importance, within the research agenda
 ✓    Over half of Uganda’s population estimated to be at risk from 
schistosomiasis; vaccine development research supported by Vector 
Control Division (VCD), Ministry of Health 
2 Safety already demonstrated  ✓    Safety data from Leiden trials ✓    Risk assessments to Uganda to be developed
3 Model quality established by published data  ✓    Publication of Leiden trials expected in 2018
4 Strong scientific case, without alternative approach
 ✓    Model has potential to fast-track selection of best vaccine candidates 
accelerating development of safe, effective vaccines
 ✓    Available animal models may not determine correlates of protection and 
vaccine efficacy in humans
 ✓    Understanding and data needed regarding differences between endemic 
and non-endemic populations in response to candidate vaccines
5 Promotes capacity development in country
 ✓    CHI-S preparatory activities already providing opportunities for learning 
and debate for researchers, ethicists and regulators; continuing interaction 
between researchers and regulators is planned
 ✓    Further developments to include relevant infrastructure development and 
technical training of Ugandan researchers
6 Ethical acceptability including issues of understanding consent
 ✓    Issues of understanding and voluntariness recognised and to be assured by 
pilot work in target populations in preparation for CHI-S
7 Governance structure in place (DSMB, sponsor)  ✓   Protocol to be developed with due attention to these requirements
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In terms of the regulatory landscape, key stakeholders in Uganda 
include the Uganda National Council for Science and Tech-
nology (UNCST), the National Drug Authority (NDA) and 
National Environment Management Agency (NEMA) as well 
as Institutional Review Boards. The roles of these authorities 
were discussed and it was concluded that the UNCST would 
hold overall authority for approval of importation of snails 
(infected or otherwise) and for review and approval of a CHI-S 
protocol. A joint review meeting, with all regulatory authorities 
represented, was recommended, as well as engagement between 
the researchers and ethical and regulatory review bodies throughout 
the process of protocol development and implementation. 
The nature of the human challenge product, the inoculum of 
infectious cercariae, was noted to present a particular dilemma. 
Whereas the product for malaria is a licensed, FDA-approved 
cryopreserved product34, the CHI-S product must be gener-
ated locally for each infection. This requires local laboratory 
capacity for high-quality production on-site, and local regula-
tory capacity for approval of the facilities and processes. Under 
these circumstances, provision of documentation correspond-
ing to the standard requirements of investigator’s brochure, cer-
tificate of good manufacturing practice, sample label, certificate 
of analysis and letter of authorisation from the product “owner” 
may be difficult, but a product dossier containing equiva-
lent information will be needed. This would be considered 
alongside full documentation of procedures and results from 
Leiden by the regulatory bodies. 
Contribution from representatives of endemic 
communities
Among representatives from endemic communities, Mr. Asuman 
Muwumuza, Councillor for Koome sub-county which com-
prises island communities in Lake Victoria, expressed strong 
support for the development of the CHI-S in Uganda. He 
assured the Meeting that local communities would understand 
the purpose of the study and want to participate, would gladly 
volunteer and would do whatever would be needed to facilitate 
these complicated trials. He felt that the need for a vaccine for 
schistosomiasis was urgent and urged the research community 
not to delay.
Conclusion and next steps
Researchers, community members and regulators participating 
in the stakeholders’ meeting expressed substantial support 
for establishing CHI-S in Uganda; this was considered both 
feasible and desirable. 
Key next steps (Table 3) include risk assessments for importa-
tion of infected snails, the development of facilities and expertise 
for production of the challenge product; community engagement 
and pilot studies to assess information and consent tools and 
comprehension by target communities, and to define appropri-
ate populations (able to avoid re-infection, and to participate with 
full understanding and as true volunteers); provision of oppor-
tunities for regulators and ethicists to learn more about CHI-S 
through visits to Leiden and engagement with their Dutch 
Table 3. Establishing a controlled human schistosome infection model in Uganda: key recommendations 
and next steps. (CHI-S) - Controlled human infection model for Schistosoma mansoni, (GCLP) - Good Clinical 
Laboratory Practice.
Technical steps
Managing and shedding 
snails in Uganda
•   Establish GCLP level facility for housing and shedding snails in Uganda 
•   Obtain accreditation of facility
Identifying male cercariae 
and preparing inoculum
•    Training Uganda team in technical and quality control and quality assurance 
procedures
Detection and quantification 
of schistosome infection in 
Uganda
•   Implementation of the highly sensitive CAA assay in Uganda
Shipping infected snails to 
Uganda
•   Risk assessment regarding environmental contamination 
•   Implementation of risk management measures 
•   Implementation of IATA shipping requirements 
•   Ensuring Material Transfer Agreements are in place prior to shipment 
•    Planning for efficient release by customs officials and handling agents on 
arrival
Protocol and participant recruitment steps
Community engagement •    Include details of planned community engagement (from parliament to local 
council) in protocol; undertake further preparatory engagement activities
Informed consent •    With social science support, develop tools to ensure and document full 
understanding by participants
Regulatory steps
Regulatory capacity building •    Provide further information for regulators and ethicists through visits to the 
Leiden facilities
CHI-S protocol for Uganda •   Draft protocol; pre-submission discussions with regulatory authorities
CHI-S product dossier •   Development of CHI-S product dossier and related documentation for Uganda
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counterparts; and development of a draft CHI-S protocol, 
product dossier and accompanying documentation for regulatory 
review.
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The open letter by AM Elliott et al. is a well-written, concise meeting summary following a stakeholders'
meeting in Entebbe, Uganda, where key individuals discussed relevant issues in establishing a controlled
human infection model for   in Uganda. The report also reviews the disease burden,Schistosoma mansoni
biology, and epidemiology of schistosomiasis. A brief update on current vaccines for schistosomiasis is
also included. The authors condense outcomes of the meeting into tabular format and relevant next-steps
to advance controlled human infection models for schistosomiasis in Uganda.
Comments:
The introduction highlights development of the  CHI model, but does not completelyS. mansoni 
describe if this model could potentially inform development of a vaccine against  alone,S. mansoni 
a model upon which  and other species could be built, or if a species-transcendingS. hematobium 
vaccine is feasible given the current state of scientific knowledge as proposed by M Merrifield in 
2016 article .Vaccine 
 
The section on epidemiology of schistosomiasis could be augmented if details on age-specific 
carriage rates in communities is available, and/or data regarding special populations hardest-hit by
schistosomiasis (immunocompromised, children, etc) can be provided. This would orient the
reader toward where vaccine efforts are most warranted.
 
The background section on schistosomiasis does not completely discuss S. hematobium 
complications, presumably because the focus of the article is on  . Consider that aS. mansoni
successful model for  could pave the way for a successful CHI model for S. mansoni S.
.hematobium
 
The section on vaccines for schistosomiasis notes that an ideal vaccine would be suitable for use
among young children. A very brief explanation as to why this population is targeted would be
informative for readers.
 
Additional considerations for Table 1 is that schistosomiasis epidemiology is dynamic and may be
difficult to predict, such that large field studies testing candidate vaccines may not show effect if
significant changes in local epidemiology occur. Also, to study infection prevention as a vaccine
trial endpoint in a population, individuals would require pre-treatment before vaccination, and this
pre-treatment may decrease community transmission significantly such that vaccine efficacy would
1
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pre-treatment may decrease community transmission significantly such that vaccine efficacy would
be difficult to measure. CHI also allows efficient testing of vaccine efficacy in individuals with a
known exposure profile and background immunity to schistosomiasis.
 
The section on endpoints in CHI studies- is parallel testing with Leiden and Uganda planned for the
PCR protein detection, or is another backup method to confirm the presence of  inS. mansoni 
place? This would be advantageous to address from a quality management perspective.
 
In addition to community engagement plans, careful risk management strategies for CHI in low and
middle-income countries are an important consideration as information management and
mitigation needs to be planned and ready to activate to mitigate undesired publicity of CHI on
social media and other avenues of communication.
 
Are there technical or infrastructure aspects of the research milieu in Uganda that made it suitable
as the first African host country for CHI for schistosomiasis? If yes, consider noting these in case
other groups are considering pilot CHI studies in low and middle-income countries.
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Page 12 of 17
AAS Open Research 2018, 1:2 Last updated: 06 AUG 2018
AAS Open Research
 
1.  
1.  
1.  
1.  
1.  
1.  
1.  
1.  
The introduction highlights development of the S. mansoni CHI model, but does not
completely describe if this model could potentially inform development of a vaccine against
S. mansoni alone, a model upon which S. hematobium and other species could be built, or if
a species-transcending vaccine is feasible given the current state of scientific knowledge as
proposed by M Merrifield in Vaccine 2016 article .
We have added two sentences on the possibility of developing a S. hematobium CHI based on the
S. mansoni blueprint trial. We feel that speculating on the feasibility of strain-transcending vaccines
is beyond the scope of the current paper, but have referred to the need to evaluate the requirement
for a hematobium model in the clinical development context.
The section on epidemiology of schistosomiasis could be augmented if details on
age-specific carriage rates in communities is available, and/or data regarding special
populations hardest-hit by schistosomiasis (immunocompromised, children, etc) can be
provided. This would orient the reader toward where vaccine efforts are most warranted.
We have added some further information in this regard. 
The background section on schistosomiasis does not completely discuss S. hematobium
complications, presumably because the focus of the article is on S. mansoni. Consider that
a successful model for S. mansoni could pave the way for a successful CHI model for S.
hematobium.
Please refer to the adaptations made in response to comment 1: we have added the possibility of
an S. hematobium model to the manuscript.
The section on vaccines for schistosomiasis notes that an ideal vaccine would be suitable
for use among young children. A very brief explanation as to why this population is targeted
would be informative for readers.
We have added a note that children would be targeted given their high burden of infection  
Additional considerations for Table 1 is that schistosomiasis epidemiology is dynamic and
may be difficult to predict, such that large field studies testing candidate vaccines may not
show effect if significant changes in local epidemiology occur. Also, to study infection
prevention as a vaccine trial endpoint in a population, individuals would require
pre-treatment before vaccination, and this pre-treatment may decrease community
transmission significantly such that vaccine efficacy would be difficult to measure. CHI also
allows efficient testing of vaccine efficacy in individuals with a known exposure profile and
background immunity to schistosomiasis.
We have added these considerations to table 1.
The section on endpoints in CHI studies- is parallel testing with Leiden and Uganda planned
for the PCR protein detection, or is another backup method to confirm the presence of S.
mansoni in place? This would be advantageous to address from a quality management
perspective.
Validation of such critical assays (as well as the CAA assay) would of course be essential to
ensure the same quality in Uganda and Leiden. Thorough validation as well as quality control
measures will be put in place to ensure this. Parallel testing could be part of this programme, but
rather an exchange of control samples with known outcomes would be more likely. We have added
a remark on this important point.
 
In addition to community engagement plans, careful risk management strategies for CHI in
low and middle-income countries are an important consideration as information
management and mitigation needs to be planned and ready to activate to mitigate
undesired publicity of CHI on social media and other avenues of communication.
We have added this point to the section on community engagement.
Are there technical or infrastructure aspects of the research milieu in Uganda that made it
1
Page 13 of 17
AAS Open Research 2018, 1:2 Last updated: 06 AUG 2018
AAS Open Research
 
1.  Are there technical or infrastructure aspects of the research milieu in Uganda that made it
suitable as the first African host country for CHI for schistosomiasis? If yes, consider noting
these in case other groups are considering pilot CHI studies in low and middle-income
countries.
We thank the reviewer for this suggestion.  We have added a short paragraph on this under the
new heading “Considerations on implementation of the novel CHI-S model in the endemic setting
in Uganda” 
 NoneCompeting Interests:
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   Sean C. Murphy
Department of Laboratory Medicine, University of Washington, Seattle, WA, USA
The report by Elliott   provides a well-written summary of schistosomiasis and the controlled humanet al.
infection (CHI) model for Schistosoma (CHI-S) developed by the Leiden team followed by an integrated
report about a stakeholders meeting conducted in Uganda ahead of possible implementation of the CHI-S
model in the endemic Uganda-based site.  
Major issues:
While the paper provides an excellent overview of schistosomiasis and the CHI-S model, the
transition from background on schistosomiasis to the report on the meeting could benefit from a
brief foreshadowing of the major findings from the stakeholders meeting.  While the technical
hurdles to implementation of the CHI-S model in Uganda were more easily identified and labeled
(and are present in Table 3), it seems more difficult to identify discrete core ethical and community
based hurdles.  The authors could consider adding more bullet points to Table 3 to expand on
some of these ethical and community based hurdles.  The authors could also add a few
overview-type sentences when the paper transitions from Background/Summary to Stakeholder
meeting report.
Minor issues:
The section titled “The controlled human schistosome infection model” could be re-titled “The
controlled human schistosome infection model and considerations for adaptation to Ugandan site”.
Is there any possibility that adoption of new strains could carry unexpected bacterial flora that
could cause unexpected AEs?
The scientific rationale for importation of the Leiden CHI-S snails/parasites as compared to use of
locally-acquired snails/parasites could be expanded upon more fully.
The following sentence is  too long and should be split into 2-3 sentences to improvemuch 
readability: “Populations of interest for CHI-S will include Ugandans not previously exposed to
schistosomiasis (perhaps from an urban setting) as well as those from schistosomiasis-endemic
communities (prior exposure for inclusion or exclusion can be determined by measuring IgG
antibody to schistosome egg antigen): experience in Kenya with the controlled human malaria
infection (CHMI) model showed that participants coming from areas with no active transmission
(Nairobi residents) had low baseline responses to malaria, and a challenge response similar to
Europeans3, whereas those resident where active malaria transmission occurs had higher
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Europeans3, whereas those resident where active malaria transmission occurs had higher
baseline responses - indicative of either recent or prior malaria exposure - and a distinct profile of
response to challenge (Kapulu, Bejon personal communication)."
Note that Sanaria's PfSPZ product is NOT yet "FDA approved".  This misunderstanding should be
corrected toward the end of the section titled “Ethical and regulatory considerations for CHI-S in
Uganda”.  The Sanaria product is being investigated under an FDA Investigational New Drug
application.
The section “Contribution from representatives of endemic communities” lists contributions from a
single individual who is said to speak for some of these communities.  However, the section title
sounds more generalized than the text indicates.  I would suggest folding this section into another
section as the current representation seems to potentially overly generalize the responses from
one (albeit generous and collaborative) individual.
Is the rationale for the Open Letter provided in sufficient detail?
Yes
Does the article adequately reference differing views and opinions?
Yes
Are all factual statements correct, and are statements and arguments made adequately
supported by citations?
Yes
Is the Open Letter written in accessible language?
Yes
Where applicable, are recommendations and next steps explained clearly for others to follow?
Yes
 No competing interests were disclosed.Competing Interests:
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I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Author Response 25 Jul 2018
, Uganda Virus Research Institute, UgandaAlison Elliott
Major issues:
While the paper provides an excellent overview of schistosomiasis and the CHI-S model,
the transition from background on schistosomiasis to the report on the meeting could benefit
from a brief foreshadowing of the major findings from the stakeholders meeting.  While the
technical hurdles to implementation of the CHI-S model in Uganda were more easily
identified and labeled (and are present in Table 3), it seems more difficult to identify discrete
core ethical and community based hurdles.  The authors could consider adding more bullet
points to Table 3 to expand on some of these ethical and community based hurdles.  The
authors could also add a few overview-type sentences when the paper transitions from
Background/Summary to Stakeholder meeting report.
We have added the requested bullet points to Table 3 to expand on the ethical and community
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Background/Summary to Stakeholder meeting report.
We have added the requested bullet points to Table 3 to expand on the ethical and community
based hurdles. In addition, we have added an introductory paragraph where the paper transitions
from describing the background to the findings in the stakeholders meeting, to ensure that the
switch is clear to the readers.
Minor issues:
The section titled “The controlled human schistosome infection model” could be re-titled
“The controlled human schistosome infection model and considerations for adaptation to
Ugandan site”.
We agree with the reviewer suggestion to make clear that we will specifically address the Ugandan
site. However, taking into account also the major issue raised by this reviewer that the transition of
the manuscript from introduction to the findings of the meeting was unclear, we have decided to do
this by adding a section title “ Considerations on implementation of the novel CHI-S model in
” to mark the transition of the paper and simultaneously indicatethe endemic setting in Uganda
the specific relevance to Uganda.
Is there any possibility that adoption of new strains could carry unexpected bacterial flora
that could cause unexpected AEs?
Infected snails are tested for their bioburden before cercaria are used for CHI-S purpose.
Potentially new strains could carry a different bioburden which would preclude their use in CHI-S,
but this needs to be tested. To highlight the fact that bioburden testing would need to take place for
new strains we have added this in our section on technical considerations.
The scientific rationale for importation of the Leiden CHI-S snails/parasites as compared to
use of locally-acquired snails/parasites could be expanded upon more fully.
We have expanded the requested paragraph.
The following sentence is much too long and should be split into 2-3 sentences to improve
readability: “Populations of interest for CHI-S will include Ugandans not previously exposed
to schistosomiasis (perhaps from an urban setting) as well as those from
schistosomiasis-endemic communities (prior exposure for inclusion or exclusion can be
determined by measuring IgG antibody to schistosome egg antigen): experience in Kenya
with the controlled human malaria infection (CHMI) model showed that participants coming
from areas with no active transmission (Nairobi residents) had low baseline responses to
malaria, and a challenge response similar to Europeans3, whereas those resident where
active malaria transmission occurs had higher baseline responses - indicative of either
recent or prior malaria exposure - and a distinct profile of response to challenge (Kapulu,
Bejon personal communication)."
We have split the sentence.
Note that Sanaria's PfSPZ product is NOT yet "FDA approved".  This misunderstanding
should be corrected toward the end of the section titled “Ethical and regulatory
considerations for CHI-S in Uganda”.  The Sanaria product is being investigated under an
FDA Investigational New Drug application.
This mistake has been corrected.
The section “Contribution from representatives of endemic communities” lists contributions
from a single individual who is said to speak for some of these communities.  However, the
section title sounds more generalized than the text indicates.  I would suggest folding this
section into another section as the current representation seems to potentially overly
generalize the responses from one (albeit generous and collaborative) individual.
We have displaced this paragraph so that it falls under the section on “recruitment considerations” 
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